CLINICAL AND EPIDEMIOLOGICAL FEATURES OF COVID-19 COURSE IN PREGNANT WOMEN.

Numerous studies have been devoted to the problem of the incidence of COVID-19 in pregnant women, but there is no sufficient evidence base to formulate specific recommendations for the management of pregnancy, prevention of perinatal complications and possible vertical transmission of the disease. The objective - to summarize clinical and epidemiological features of COVID-19 course and outcomes of labor in pregnant women in the Odessa region (Ukraine). 218 case histories of pregnancy and childbirth of women hospitalized to the specialized hospital base "Maternity hospital No. 2" of the Odessa City Council (Ukraine) with diagnosis of COVID-19, have been analyzed. The diagnosis was verified by the PCR. The study was conducted from 01.03.2020 to 31.01.2021. The incidence of COVID-19 in pregnant women from April 2020 to January 2021 increased from 3.7% to 63.1% of the total number of births. Among the patients the city dwellers predominated (65.2%), women were more likely to get sick in the 3rd trimester (67.4%). 58.8% of women were overweight. 53.2% of the patients under observation were diagnosed with 2-sided polysegmental pneumonia; hyperthermia was noted in 71.2% of pregnant. The incidence of ARDS was noted in 10.1% of cases. An increase in the level of D-dimers was revealed in 72.4% of cases, and in 57.3% - in the level of CRP. All pregnant women recovered, 7.8% needed therapy in the intensive care unit. 86.5% of women gave birth on time, 9.9% of women had premature labour; 3.6% had an abortive outcome. The caesarean section rate constituted 29.7% (OR= 1.61 95% 0.85 3.06; Р>0,05). The prevalence of COVID-19 among pregnant women in the Odessa region is characterized by a common situation for a pandemic. Violation of fat metabolism in pregnant women is a significant risk factor for the incidence of COVID-19 (OR 2.25 95% CI 1.98-3.96; Р<0.05). COVID-19 is a risk factor for increased pre-term births and early pregnancy losses (OR=4.23 95% CI 1.35 - 13.25; Р < 0.05). Further multicenter studies are needed to obtain reliable data on the impact of COVID-19 on pregnant women and intrauterine patients.